{"groups":[{"description":"Double-blind period: Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle. Open-label (OL) period: Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle.","id":"FG000","title":"DB Sorafenib First, Then Option of OL Sorafenib Treatment"},{"description":"Double-blind period: participants received matching placebo tablets orally twice daily, 28 days comprised a cycle. Open-label (OL) period: participants on placebo who switched to sorafenib, received sorafenib 400 mg (2 x 200 mg) orally twice daily, 28 days comprise a cycle.","id":"FG001","title":"DB Placebo First, Then Option of OL Sorafenib Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"3"}],"type":"Progression, recurrence or relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Noncompliance with study medication"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Progression by clinical judgment"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"18"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}],"type":"Switched to commercial drug"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"protocol driven decision point"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Radiological and clinical progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Transferred to treat. continuation study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"207"},{"groupId":"FG001","numSubjects":"210"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects at Risk/Safety Population - in RG1 (RG= Reporting Group for Safety Data)","groupId":"FG000","numSubjects":"207"},{"comment":"Subjects at Risk/Safety Population - in RG2 (RG= Reporting Group for Safety Data)","groupId":"FG001","numSubjects":"209"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"103"},{"groupId":"FG001","numSubjects":"172"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"38"}],"type":"NOT COMPLETED"}],"title":"Double Blind Treatment"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"30"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"15"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"82"}],"type":"Progression, recurrence or relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Patient convenience"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Non-compliant with study medication"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Target lesion removed"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol driven decision point"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Transferred to treat. continuation study"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"}],"type":"Switched to commercial drug"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"86"},{"groupId":"FG001","numSubjects":"161"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects at Risk/Safety Population - in RG3 (RG= Reporting Group for Safety Data)","groupId":"FG000","numSubjects":"86"},{"comment":"Subjects at Risk/Safety Population - in RG4 (RG= Reporting Group for Safety Data)","groupId":"FG001","numSubjects":"161"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"86"},{"groupId":"FG001","numSubjects":"161"}],"type":"NOT COMPLETED"}],"title":"Open-label Treatment"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"68"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"26"}],"type":"Protocol driven decision point"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Transferred to treat. continuation study"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Switched to commercial drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease prog., recurrence or relapse"}],"milestones":[{"achievements":[{"comment":"Participants entered long-term follow-up if terminated double-blind or open-label periods","groupId":"FG000","numSubjects":"72"},{"comment":"Participants entered long-term follow-up if terminated double-blind or open-label periods","groupId":"FG001","numSubjects":"124"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"120"}],"type":"NOT COMPLETED"}],"title":"Long Term Follow-up"}],"preAssignmentDetails":"Of 556 screened participants, 137 failed screening, 207 were randomized to receive sorafenib, 210 were randomized to placebo."}